Nahila Justo1, Manuel A Espinoza2, Barbara Ratto3, Martha Nicholson4, Diego Rosselli5, Olga Ovcinnikova6, Sebastián García Martí7, Marcos B Ferraz8, Martín Langsam9, Michael F Drummond10. 1. Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; Real World Evidence, Strategy and Analytics, ICON plc, Stockholm, Sweden. Electronic address: nahila.justo@ki.se. 2. Department of Public Health, Pontificia Universidad Católica del Chile, Santiago, Chile. 3. Novartis Pharmaceuticals Corp, East Hanover, NJ, USA. 4. Real World Evidence, Strategy and Analytics, ICON plc, Stockholm, Sweden. 5. Clinical Epidemiology and Biostatistics Department, Pontificia Universidad Javeriana, Bogatá, Colombia. 6. HTA Strategy and Analytics, ICON plc, London, England, UK. 7. Institute for Clinical Effectiveness and Public Health, Buenos Aires, Argentina. 8. Federal University of São Paulo, São Paulo, Brazil. 9. University Isalud, Buenos Aires, Argentina. 10. Centre for Health Economics, University of York, York, England, UK.
Abstract
BACKGROUND: Real-world evidence (RWE) is increasingly used to inform health technology assessments for resource allocation, which are valuable tools for emerging economies such as in America. Nevertheless, the characteristics and uses in South America are unknown. OBJECTIVES: To identify sources, characteristics, and uses of RWE in Argentina, Brazil, Colombia, and Chile, and evaluate the context-specific challenges. The implications for future regulation and responsible management of RWE in the region are also considered. METHODS: A systematic literature review, database mapping, and targeted gray literature search were conducted to identify the sources and characteristics of RWE. Findings were validated by key opinion leaders attending workshops in 4 South American countries. RESULTS: A database mapping exercise revealed 407 unique databases. Geographic scope, database type, population, and outcomes captured were reported. Characteristics of national health information systems show efforts to collect interoperable data from service providers, insurers, and government agencies, but that initiatives are hampered by fragmentation, lack of stewardship, and resources. In South America, RWE is mainly used for pharmacovigilance and as pure academic research, but less so for health technology assessment decision making or pricing negotiations and not at all to inform early access schemes. CONCLUSIONS: The quality of real-world data in the case study countries vary and RWE is not consistently used in healthcare decision making. Authors recommend that future studies monitor the impact of digitalization and the potential effects of access to RWE on the quality of patient care.
BACKGROUND: Real-world evidence (RWE) is increasingly used to inform health technology assessments for resource allocation, which are valuable tools for emerging economies such as in America. Nevertheless, the characteristics and uses in South America are unknown. OBJECTIVES: To identify sources, characteristics, and uses of RWE in Argentina, Brazil, Colombia, and Chile, and evaluate the context-specific challenges. The implications for future regulation and responsible management of RWE in the region are also considered. METHODS: A systematic literature review, database mapping, and targeted gray literature search were conducted to identify the sources and characteristics of RWE. Findings were validated by key opinion leaders attending workshops in 4 South American countries. RESULTS: A database mapping exercise revealed 407 unique databases. Geographic scope, database type, population, and outcomes captured were reported. Characteristics of national health information systems show efforts to collect interoperable data from service providers, insurers, and government agencies, but that initiatives are hampered by fragmentation, lack of stewardship, and resources. In South America, RWE is mainly used for pharmacovigilance and as pure academic research, but less so for health technology assessment decision making or pricing negotiations and not at all to inform early access schemes. CONCLUSIONS: The quality of real-world data in the case study countries vary and RWE is not consistently used in healthcare decision making. Authors recommend that future studies monitor the impact of digitalization and the potential effects of access to RWE on the quality of patient care.
Authors: Milou A Hogervorst; Johan Pontén; Rick A Vreman; Aukje K Mantel-Teeuwisse; Wim G Goettsch Journal: Front Pharmacol Date: 2022-02-10 Impact factor: 5.810
Authors: Julia Simões Corrêa Galendi; Carlos Antonio Caramori; Clarissa Lemmen; Dirk Müller; Stephanie Stock Journal: Int J Environ Res Public Health Date: 2021-11-13 Impact factor: 3.390
Authors: Eliya Farah; Maria El Bizri; Radmila Day; Lavina Matai; Fred Horne; Timothy P Hanna; David Armstrong; Susan Marlin; Olivier Jérôme; Darren R Brenner; Winson Cheung; Laszlo Radvanyi; Eva Villalba; Natalie Leon; Chana Cohen; Karine Chalifour; Ronald Burkes; Sharlene Gill; Scott Berry; Brandon S Sheffield; Pamela Fralick; Barry D Stein Journal: Curr Oncol Date: 2022-03-07 Impact factor: 3.677